LL-37
Cathelicidin antimicrobial peptide
Mechanism of Action
Human cathelicidin antimicrobial peptide. Disrupts bacterial membranes, promotes wound healing, modulates immune response, and stimulates angiogenesis.
Key Benefits
- Broad-spectrum antimicrobial activity
- Wound healing acceleration
- Immune modulation
- Anti-biofilm properties
Dosing Protocol
Strong antimicrobial and wound healing data. Pharmacy counsel required.
Ideal Candidates
Chronic wounds, infections, immune support.
Side Effects & Safety
Injection site reactions, potential inflammatory response at high doses.
Regulatory Status
Gray AreaNot on the 503A bulks list. Gray zone — pharmacy counsel required.
Frequently asked
What is LL-37?+
LL-37 (Cathelicidin antimicrobial peptide) is a peptide studied for antimicrobial and wound healing. Human cathelicidin antimicrobial peptide. Disrupts bacterial membranes, promotes wound healing, modulates immune response, and stimulates angiogenesis.
What is the dosing protocol for LL-37?+
Literature commonly references 1 mg 3x/wk (low) to 2 mg 5x/wk (maintenance) via SubQ / Topical, on a 4–8 weeks cycle. Educational reference only — a licensed Stackhaus Health provider sets any personalized protocol.
What is the regulatory status of LL-37?+
Not on the 503A bulks list. Gray zone — pharmacy counsel required.
Where can I access LL-37?+
Research-grade LL-37 is available through Stackhaus Research. For a personalized, provider-reviewed protocol, consult a licensed clinician through Stackhaus Health.